Skip to main content

Milestone 9.F

Initiate studies to develop minimally invasive biomarkers for detection of cerebral amyloidosis, AD, and related dementias pathophysiology.

Success Criteria

Development and testing of 5 biomarkers that utilize biofluids or other minimally invasive imaging, electrophysiological recording, or other methodologies to assess the burden of AD and ADRD pathophysiology that could be used in community based and epidemiological studies of AD and related dementias.

Time Required

2015 to 2019

Research Implementation Area

Biomarkers

CADRO Category

B. Diagnosis, Assessment and Disease Monitoring

Activities, Funding Initiatives, and Resources

NIH PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting…
NIH RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01)
PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting Pro…
NNIH RFA-AG-15-011: Biomarkers of Alzheimer's Disease in Down Syndrome (R01)
NIH PA-16-091: Small Business Alzheimer's Disease Research (R43/R44)
NIH PA-16-092: Small Business Alzheimer's Disease Research (R41/R42)
NIH RFA-AG-16-019: Limited Competition: Alzheimer's Disease Neuroimaging Initia…
NIH PAR-18-183: T1 Translational Research on Aging: Small Business Innovation A…
NIH PAS-18-188: Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-…

Funded Research Projects

IADRP – Category B. Diagnosis, Assessment and Disease Monitoring - 1. Fluid Bio…
IADRP – 2. Imaging Biomarkers
NIH PAR-15-359: Novel Approaches to Diagnosing Alzheimer's Disease & Predicting…
NIH RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01) – R…